Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Update

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,710,000 shares, a decline of 5.5% from the May 31st total of 1,810,000 shares. Based on an average trading volume of 302,500 shares, the days-to-cover ratio is currently 5.7 days.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several large investors have recently made changes to their positions in ATNM. Virtu Financial LLC grew its stake in shares of Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 62,459 shares during the period. Vanguard Group Inc. boosted its position in shares of Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the last quarter. Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals during the 1st quarter valued at about $78,000. Finally, Creative Financial Designs Inc. ADV boosted its position in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 3,175 shares during the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Stock Down 3.3 %

Shares of NYSEAMERICAN:ATNM opened at $6.96 on Wednesday. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $10.24. The firm has a market capitalization of $207.27 million, a price-to-earnings ratio of -4.07 and a beta of 0.20.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.11. On average, equities analysts forecast that Actinium Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ATNM shares. Maxim Group lifted their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, June 17th. Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. Finally, StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, May 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.60.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.